Quality Assurance of Pharmaceuticals - A Compendium of Guidelines and Related Materials - Volume 1
(1997; 248 pages) [French] Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoIntroduction
Cerrar esta carpeta1. National drug regulation
Cerrar esta carpetaGuiding principles for small national drug regulatory authorities1,2
Abrir esta carpeta y ver su contenido1. General considerations
Cerrar esta carpeta2. Administrative aspects of the licensing process
Ver el documento2.1 Provisional registration of existing medicinal products
Ver el documento2.2 Screening of provisionally registered products
Ver el documento2.3 New product licences
Ver el documento2.4 Renewal and variation of licences
Abrir esta carpeta y ver su contenido3. Technical aspects of the licensing process
Abrir esta carpeta y ver su contenido2. Product assessment and registration
Abrir esta carpeta y ver su contenido3. Distribution
Abrir esta carpeta y ver su contenido4. The international pharmacopoeia and related activities
Abrir esta carpeta y ver su contenido5. Basic tests
Abrir esta carpeta y ver su contenido6. Laboratory services
Abrir esta carpeta y ver su contenido7. International trade in pharmaceuticals
Abrir esta carpeta y ver su contenido8. Counterfeit products
Abrir esta carpeta y ver su contenido9. Training
Ver el documentoSelected WHO publications of related interest
Ver el documentoBack cover
 
2.1 Provisional registration of existing medicinal products

Before any system of control can become effective, it is necessary to identify and catalogue all products already sold or otherwise supplied on the domestic market, in both the public and the private sectors, that qualify for control. To this end, all manufacturers and importing agencies must be given reasonable notice through official gazettes, the trade press and other media of their obligation to notify the authority by a specific date of all medicinal products that they currently distribute within the jurisdiction of the authority and that they intend to continue to supply after a duly appointed day, on which licensing requirements enter into operation. After the appointed day no medicinal product may lawfully be distributed or supplied unless its existence has been notified to the authority, and no new product may be introduced until a request for a product licence has been granted by the authority.

Effective administration of the provisional registration procedure is dependent upon:

(a) prior identification of all interested manufacturers and importers;

(b) a precise definition of a notifiable medicinal product based primarily on the labelled claims and the indications for use;

(c) the issuance of guidelines on the procedure to be followed.

Each notified product must be identified by name (either brand or generic), the names and full addresses of the manufacturer and importing agent, a description of the dosage form, its composition - including active and inactive ingredients (using international nonproprietary names where appropriate) - the therapeutic class, the indications, a copy of all labelling, including any package insert, and a copy of any relevant certificates and warranties relating to the product or its components.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013